top of page


John Mattick AO, FAA, FAHMS, FRSN, HonFRCIPA, BSc (Hons), PhD Nominee Board Director


John is a highly acclaimed geneticist who is currently a Senior Research Fellow at Green Templeton College, Oxford. He was most recently Chief Executive of Genomics England (2018-2019), and Director of the Garvan Institute of Medical Research in Sydney (2012-2018). He has received many honours and awards for his work on the human genome and he has published over 300 scientific papers.

Steve Averbuch M.D.


Steve is an NCI (National Cancer Institute) trained academic medical oncologist.

He has 35+ years oncology drug development experience and 10+ years biomarker and drug-diagnostic co-development. He has led multiple drug and companion diagnostic approvals in US and other major markets. 

Steve has also driven technical and clinical business development due diligence and alliance partnerships.

He is a strategic builder and leader of clinical research and translational medicine organizations.

Bob Barrett B.S.


Bob has over 25 years of combined experience in commercial operations and general management in Clinical Diagnostics and Applied Markets. He has  extensive experience in commercializing novel technologies in healthcare and life science markets. His experiences include infectious disease molecular diagnostics, applied markets, and life science research and product development.

Companies where he has worked include Roche Molecular, Chiron Diagnostics, Qiagen and Abbott (US based). 


Matt Kilpatrick

Corporate Advisor Dip. FP, Adv. Dip. FP

Matt is an experienced executive and corporate advisor providing commercialisation and strategic business development advisory. Matt has successfully executed numerous business development and advisory roles, lead capital raising initiatives, provided strategic business direction for start-ups and established entities that are seeking scale or a liquidity event. Matt is known for implementing M&A strategies and providing effective leadership via a “hands on” approach to achieve solid founder and investor returns.

bottom of page